reports
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
ACRS ACLARIS THERAPEUTICS INC.
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ORIC KEROS THERAPEUTICS
ZNTL ORIC PHARMACEUTICALS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PLTK SANA BIOTECHNOLOGY
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
EWTX PEPGEN INC
SLDB EDGEWISE THERAPEUTICS INC
DDI SOLID BIOSCIENCES INC
APGE DOUBLEDOWN INTERACTIVE CO LTD
EMBRAC B APOGEE THERAPEUTICS INC
DNTH EMBRACER GROUP AB
ORKA DIANTHUS THERAPEUTICS INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
IMA JADE BIOSCIENCES INC
IMAGENEBIO INC.
- David Nierengarten
- Dennis Pak
- Martin Fan
- Wedbush Research
ACRS ACLARIS THERAPEUTICS INC.
CCRN CROSS COUNTRY HEALTHCARE INC.
ANAB ANAPTYSBIO INC.
AAPL APPLE INC.
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
VRDN VIRIDIAN THERAPEUTICS INC
VOR VOR BIOPHARMA
BUR BURFORD CAPITAL
TMC THE METALS COMPANY INC
PEPG PEPGEN INC
BCAX BICARA THERAPEUTICS INC.
EIKN EIKON THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Martin Fan
Results Presented at 2026 American Academy of Dermatology (AAD) Annual...
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 - Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its Phase 2a trial of ATI-2138...
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial o...
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), wil...
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitu...
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line re...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
ETSY ETSY INC.
EBAY EBAY INC.
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
CHWY CHEWY INC. CLASS A
SMCI SUPER MICRO COMPUTER
IDYA INC.
DASH IDEAYA BIOSCIENCES
PLTR DOORDASH
STX PALANTIR TECHNOLOGIES
TMC SEAGATE TECHNOLOGY HLDGS PLC
GFS THE METALS COMPANY INC
PL GLOBALFOUNDRIES INC
APGE PLANET LABS PBC
DNTH APOGEE THERAPEUTICS INC
CRBP DIANTHUS THERAPEUTICS INC
CART CORBUS PHARMACEUTICALS HOLDINGS INC.
RNAC MAPLEBEAR INC.
TLX CARTESIAN THERAPEUTICS INC
VOYG TELIX PHARMACEUTICALS LIMITED
VOYAGER TECHNOLOGIES INC
- David Nierengarten
- Dennis Pak
- Martin Fan
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Globa...
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday March 10, 2026, at 1:40 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners 2026 Global Healthcare Conference in Miami, FL. A live a...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financi...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candida...
- David Nierengarten
- Dennis Pak
- Martin Fan
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Pati...
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody, in asthma. This announcement follo...
Aclaris Therapeutics to Participate in Two February Healthcare Confere...
Aclaris Therapeutics to Participate in Two February Healthcare Conferences WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in February 2026. On Thursday February 12, 2026, at 2:30 PM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Gug...
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates R...
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) - ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a mur...
- Wedbush Research
- David Nierengarten
- Dennis Pak
- Martin Fan
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
VRNS VARONIS SYSTEMS INC.
TSLA TESLA INC
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QLYS QUALYS INC.
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FTNT FORTINET INC.
FB FACEBOOK INC. CLASS A
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
NFLX NETFLIX INC.
INOD INNODATA
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
TENB TENABLE HOLDINGS
ESTC ELASTIC N.V.
LYFT LYFT
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
U INC.
TLS UNITY SOFTWARE
DASH TELOS
AI DOORDASH
PLTR C3.AI
VRDN PALANTIR TECHNOLOGIES
IMNM VIRIDIAN THERAPEUTICS INC
PLTK IMMUNOME
STX PLAYTIKA HOLDING
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
PL GLOBALFOUNDRIES INC
S PLANET LABS PBC
TYRA SENTINELONE INC
ARTV TYRA BIOSCIENCES INC
SERV ARTIVA BIOTHERAPEUTICS INC
SNDK SERVE ROBOTICS INC
SANDISK CORP
- Alicia Reese
- Antoine Legault
- Daniel Ives
- David Nierengarten
- Laura Chico
- Martin Fan
- Matthew Bryson
- Matthew McCartney
- Robert Driscoll
- Scott Devitt
- Seth Basham
- Yun Zhong
VRNS VARONIS SYSTEMS INC.
TSLA TESLA INC
TRIP TRIPADVISOR INC.
QLYS QUALYS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
MELI MERCADOLIBRE INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
INOD INNODATA
WVE WAVE LIFE SCIENCES
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
TENB TENABLE HOLDINGS
ESTC ELASTIC N.V.
LYFT LYFT
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
U UNITY SOFTWARE
TLS TELOS
DASH DOORDASH
AI C3.AI
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
APP APPLOVIN CORP
S SENTINELONE INC
TYRA TYRA BIOSCIENCES INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SERV SERVE ROBOTICS INC
SNDK SANDISK CORP
- Wedbush Research
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
PTGX PROTAGONIST THERAPEUTICS
ARGX ARGENX ADS
ISR ISORAY
AAPL APPLE INC.
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
ORIC ORIC PHARMACEUTICALS
COGT COGENT BIOSCIENCES INC
NUVB NUVATION BIO INC (A)
PL PLANET LABS PBC
GMTX GEMINI THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
NUVL NUVALENT INC
SYRE SPYRE THERAPEUTICS INC.
ORKA ORUKA THERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.